Immunotherapy for Lynch Syndrome Patients

Patients with DNA mismatch repair deficient (dMMR) microsatellite instability (MSI) metastatic colorectal cancer, including Lynch syndrome, are a distinct population who benefit less from conventional chemotherapy and have a shorter overall survival than do patients with proficient MMR (pMMR) metastatic colorectal cancer. However, after the clinical breakthrough of monoclonal antibody-based immune checkpoint blockade therapies that enhance the function of antitumor T lymphocytes, the treatment of such dMMR-associated recurrent/metastatic cancers has drastically changed. This chapter aims to review some of the many advances in immunotherapy for Lynch syndrome patients with advanced cancers.